A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
A randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for locally advanced Unresectable or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
DRUG: AK104|DRUG: Placebo
Overall Survival (os), OS in the ITT population., Up to 2 years
ORR, ORR is the proportion of subjects with CR or PR based on RECIST v1.1, Up to 2 years|DCR, DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1, Up to 2 years|DoR, DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first., Up to 2 years|TTR, TTR is defined as the time to response base on RECIST v1.1, Up to 2 years|PFS, PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first assessed by investigator Per RECIST 1.1, Up to 2 years|AE, Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and clinically significant abnormal laboratory results., From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first|Observed concentrations of AK104, The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration, From first dose of AK104 through the last dose of AK104, about average of 9 months.|Number of subjects who develop detectable anti-drug antibodies (ADAs), The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs)., From first dose of AK104 through 30 days after last dose of AK104
A randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for locally advanced Unresectable or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.